Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Weide, B; Eigentler, TK; Pflugfelder, A; Zelba, H; Martens, A; Pawelec, G; Giovannoni, L; Ruffini, PA; Elia, G; Neri, D; Gutzmer, R; Becker, JC; Garbe, C.
Intralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responses.
Cancer Immunol Res. 2014; 2(7):668-678 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG


Autor/innen der Med Uni Graz:
Becker Jürgen Christian

Dimensions Citations:

Plum Analytics:
L19-IL2 is a recombinant protein comprising the cytokine IL2 fused to the single-chain monoclonal antibody L19. In previous studies, intralesional injection with IL2 has shown efficacy for the locoregional treatment of cutaneous/subcutaneous metastases in patients with advanced melanoma. The objectives of this study were to investigate whether (i) intralesional delivery of a targeted form of IL2 would yield similar results, with reduction of injection frequency and treatment duration; and (ii) systemic immune responses were induced by the local treatment. Patients with stage IIIB/IIIC melanoma and cutaneous/subcutaneous injectable metastases received weekly intratumoral injections of L19-IL2 at a maximum dose of 10 MIU/week for 4 consecutive weeks. Tumor response was evaluated 12 weeks after the first treatment. Twenty-four of 25 patients were evaluable for therapy-induced responses. A complete response (CR) by modified immune-related response criteria (irRC) of all treated metastases was achieved in 6 patients (25%), with long-lasting responses in most cases (5 patients for ≥24 months). Objective responses were documented in 53.9% of all index lesions [44.4% CR and 9.5% partial responses (by irRC)], and 36.5% of these remained stable, while 9.5% progressed. Toxicity was comparable with that of free IL2, and no serious adverse events were recorded. A significant temporary increase of peripheral regulatory T cells and natural killer cells, sustained increase of absolute CD4(+) lymphocytes, and decrease of myeloid-derived suppressor cells were observed upon treatment. Finally, we recorded encouraging data about the progression time to distant metastases and overall survival. ©2014 American Association for Cancer Research.
Find related publications in this database (using NLM MeSH Indexing)
Adult -
Aged -
Aged, 80 and over -
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - therapeutic use
Disease Progression -
Drug Administration Schedule -
Female -
Humans -
Injections, Intralesional -
Kaplan-Meier Estimate -
Male -
Melanoma - drug therapy
Melanoma - immunology
Melanoma - pathology
Melanoma - secondary
Middle Aged -
Neoplasm Staging -
Recombinant Fusion Proteins - administration & dosage
Recombinant Fusion Proteins - therapeutic use
Skin Neoplasms - drug therapy
Skin Neoplasms - immunology
Skin Neoplasms - pathology
Skin Neoplasms - secondary
T-Lymphocyte Subsets - immunology
Treatment Outcome -

© Meduni Graz Impressum